Survodutide is an investigational dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Unlike tirzepatide (GIP/GLP-1), survodutide combines glucagon and GLP-1 agonism, adding glucagon-driven hepatic fat oxidation and energy expenditure to GLP-1-mediated appetite suppression. It has shown particular promise for MASH (metabolic dysfunction-associated steatohepatitis), achieving MASH resolution in 83% of patients at the highest dose in Phase 2, and is in Phase 3 trials for both obesity and MASH.
Category: Metabolic / Dual Agonist. Evidence rating: B (meaningful human data).
Clinical status: Phase 3 clinical trials for MASH and obesity (Boehringer Ingelheim)
Survodutide simultaneously activates glucagon receptors (increasing hepatic fat oxidation, energy expenditure, and thermogenesis) and GLP-1 receptors (reducing appetite, slowing gastric emptying, improving insulin secretion). The glucagon component specifically drives hepatic lipid mobilization —…
Research base: 31 registered clinical trials and 37 indexed publications reference Survodutide.
Safety considerations: GI adverse events (nausea, vomiting, diarrhea) similar to other incretin-based therapies; Heart rate increases observed (class effect); Dose-dependent tolerability — titration essential.
Reviewed by the PeptideAtlas Editorial Team. Last reviewed: 2026-07-05.
Survodutide is a glucagon/GLP-1 dual agonist. Tirzepatide is a GIP/GLP-1 dual agonist. Retatrutide is a GIP/GLP-1/glucagon triple agonist. Survodutide's glucagon component specifically targets liver fat, making it particularly promising for MASH. Retatrutide includes all three mechanisms.
Survodutide is a dual GLP-1 and glucagon receptor agonist being researched as a next-generation weight loss peptide with potential liver health benefits.
SURVODUTIDE has been studied for: Weight loss research, Dual mechanism, Liver health potential. GLP-1/glucagon dual agonist; emerging weight loss research.
Dual agonist that combines GLP-1 appetite suppression with glucagon's fat-burning and hepatic effects.